<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368573">
  <stage>Registered</stage>
  <submitdate>18/05/2015</submitdate>
  <approvaldate>1/10/2015</approvaldate>
  <actrnumber>ACTRN12615001027505</actrnumber>
  <trial_identification>
    <studytitle>Effect of Nitrates on Bone Density</studytitle>
    <scientifictitle>Efficacy of nitrates on bone mineral density in postmenopausal women with osteopenia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1, isosorbide mononitrate 20mg daily, immediate release, oral for 1 year then no intervention for 1 year
Arm 2, isosorbide mononitrate 30mg daily, sustained release, oral for 1 year then no intervention for 1 year
Arm 3, isosorbide mononitrate 60mg daily, sustained release, oral for 1 year then no intervention for 1 year
Arm 4, nitroglycerin 25 mg daily, transdermal  for 1 year then no intervention for 1 year
Arm 5, nitroglycerin 50 mg daily, transdermal  for 1 year then no intervention for 1 year

Treatment adherence will be monitored in the trial by count of tablet or patches returned at the 6 month and 1 year visits.</interventions>
    <comparator>Arm 6 Placebo, tablet daily  for 1 year then no intervention for 1 year
Arm 7 Placebo, patch daily for 1 year then no intervention for 1 year</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in lumbar spine bone mineral density assessed on DXA scans</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total hip bone mineral density assessed on DXA scans</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in femoral neck bone mineral density assessed on DXA scans</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total body bone mineral density assessed on DXA scans</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in markers of bone turnover (procollagen type-I N-terminal propeptide, P1NP, and Beta-C-terminal telopeptide of type I collagen, CTX, assessed using via serum assay)</outcome>
      <timepoint>1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in markers of bone turnover (procollagen type-I N-terminal propeptide, P1NP, and Beta-C-terminal telopeptide of type I collagen, CTX, assessed using via serum assay)</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in lumbar spine bone mineral density assessed on DXA scans</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total hip bone mineral density assessed on DXA scans</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in femoral neck bone mineral density assessed on DXA scans</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in total body bone mineral density assessed on DXA scans</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Postmenopausal women aged &gt;55 years
2. Bone mineral density T score at the lumbar spine, femoral neck or total hip between -1 and -2.5
</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Bone mineral density T score &lt;-2.5 at the total hip, femoral neck or lumbar spine
2. Current use of nitrate agents, or phosphodiesterase-5 inhibitors
3. Concurrent major systemic illness including untreated hypothyroidism or hyperthyroidism, chronic liver disease, chronic renal failure, malignancy, and active major gastrointestinal disease
4. Known congenital heart disease or hypotension, systolic blood pressure &lt; 100 mmHg
5. Metabolic bone disease 
6. Previous fragility fracture of the hip or clinical spine fracture
7. Current or past use of bisphosphonate therapy within 12 months, or any past zoledronate use
8. Use of oral glucocorticoid drugs equivalent to an average dose of at least prednisone 2.5mg/day during the preceding 6 months
9. Use of hormone replacement therapy within 12 months
10. Known nitrate hypersensitivity
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Permuted block randomisation with blocks of varying size.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>30/11/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>Private Bag 92019,
Auckland, 1142
New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541,
Wellesley Street,
Auckland 1141
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Fractures occur in more than 50% of older women. Low bone density is a strong risk factor for fracture, but 80% of fractures occur in women with only mildly low bone density. Currently, there are no acceptable evidenced-based treatments for these women. Small studies have suggested that organic nitrates, which are commonly used to treat heart disease, might increase bone density. We plan to systematically investigate their effects on bone density. We will undertake a 2-year randomised, placebo-controlled trial of 5 different doses of organic nitrates in post-menopausal women with mildly low bone density. Participants will receive organic nitrates or inactive treatment for 1 year and then will be followed without treatment for 1 year. The main outcome is the change in bone density. If the treatment is effective, the study will provide the evidence base for a large trial to be conducted to test whether these agents can prevent fractures.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern B Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Ethics Department
Freyberg Building
Reception  Ground Floor
20 Aitken Street
Wellington 6011</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>18/05/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Mark Bolland</name>
      <address>Department of Medicine
University of Auckland
Private Bag 92019
Auckland 1142</address>
      <phone>64 9 373 7599</phone>
      <fax>64 9 373 7677</fax>
      <email>m.bolland@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Anne Horne</name>
      <address>Department of Medicine
University of Auckland
Private Bag 92019
Auckland 1142</address>
      <phone>64 9 373 7599</phone>
      <fax>64 9 373 7677</fax>
      <email>a.horne@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mark Bolland</name>
      <address>Department of Medicine
University of Auckland
Private Bag 92019
Auckland 1142</address>
      <phone>64 9 373 7599</phone>
      <fax>64 9 373 7677</fax>
      <email>m.bolland@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>